Physician profile
Wesley Spruill
NPI 1184618969
$2,363.45
in general payments reported to CMS, 2019-2025
24 companies · $206 in 2025
The $206 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $280 · 2021: $223 · 2022: $421 · 2023: $328 · 2024: $160 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $693.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $709.84 | 2019-2025 | Spectra Wavewriter, Wavewriter Alpha Prime 16, Artisan |
| Vertos Medical, INC. | $425.90 | 2019-2024 | Mild Device Kit |
| Amgen INC. | $239.70 | 2019-2024 | Evenity, Prolia |
| Collegium Pharmaceutical, INC. | $152.90 | 2019-2024 | Xtampza, Belbuca |
| Pacira Therapeutics, INC. | $108.57 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $88.14 | 2019-2022 | |
| Redhill Biopharma INC. | $86.64 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $75.74 | 2023-2024 | Horizant, Horizant |
| Pfizer INC. | $67.88 | 2019 | |
| Forte Bio-Pharma LLC | $62.08 | 2022-2024 | Prolate, Nalocet |
| Abbott Laboratories | $55.75 | 2025 | Proclaim |
| Vertex Pharmaceuticals Incorporated | $38.17 | 2024-2025 | |
| Horizon Therapeutics Plc | $38.00 | 2019-2020 | |
| Spr Therapeutics, INC | $30.51 | 2025 | Sprint Pns System |
| Globus Medical, INC. | $29.75 | 2025 | Senza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $26.94 | 2019 | |
| Tersera Therapeutics LLC | $23.80 | 2019 | |
| Relievant Medsystems, INC. | $21.21 | 2022 | |
| Pernix Therapeutics Holdings, INC. | $16.09 | 2019 | |
| Almatica Pharma LLC | $15.05 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.26 | 2022 | |
| Medtronic, INC. | $13.20 | 2024 | Intellis Adaptivestim |
| Kowa Pharmaceuticals America, INC. | $12.24 | 2022 | |
| Zyla Life Sciences, INC. | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Spruill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.